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Eur J Vasc Endovasc Surg (2011) 41, 294e295CORRESPONDENCEComment on “What is the Place of Surgery for
Intermittent Claudication?”Dear Editor,
In their editorial What is the place of surgery for
intermittent claudication?,1 Campbell and Birchley argue
that surgery can offer benefits in terms of health-related
quality of life (HRQL). However, whether surgery is in fact
a worthwhile endeavour remains unclear. The Swedish
Board of Technology Assessment in Health Care (SBU)
concluded in 2007 that there is only limited evidence for
improved HRQL by revascularisation in IC patients.
The authors suggest that decisions about interventions
for IC are unlikely to be better informed by controlled
studies due to poor patient recruitment, referring to the
MIMIC trial.2 We are convinced that Campbell and Birchley
would agree that conclusions regarding the effectiveness of
technologies are best based on controlled trials. Recruit-
ment into trials can be improved by less selective inclusion
criteria allowing open surgical and/or endovascular revas-
cularisation and also allowing invasive treatment for the
occasional non-invasive group patient that deteriorates
significantly. In a randomised study of surgical/endovas-
cular versus non-invasive treatment,3 we included approx-
imately 60% of referred claudicants 85 years. Presently,
we include 61% in a new study with similar inclusion
criteria but updated interventions.
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Response to comment on “What Is The Place Of
Surgery For Intermittent Claudication?”Dear Editor,
We thank Jivega˚rd et al for their interest in our editorial.
We do not argue that surgical revascularisation is anything
more than an option to be considered where anatomical
patterns of disease and patient choice support it. “Limited
evidence” is not the same as “No evidence” and in a field as
difficult to study scientifically as revascularisation in clau-
dication this distinction becomes the more important. In
the absence of large and definitive randomised controlled
trials we are left to make judgements about individual
patients with the available evidence.
In terms of expanding the scope of future trials, the
double-edged sword is that more lax criteria for trial entry
and types of intervention will arguably lead to reduced
certainty about the place of particular types of treatment.
We certainly do support the value of adequately poweredDOI of original article: 10.1016/j.ejvs.2010.10.012.
Correspondence 295prospective randomised controlled trials. We wish Jivega˚rd
and colleagues well with their current study and look
forward to seeing the results.
D. Birchley*
B. Campbell
Royal Devon and Exeter Hospital,
Vascular Surgery, Barrack Road,
Exeter, United Kingdom
*Corresponding author.
E-mail address: dbirchley@hotmail.com (D. Birchley)
Available online 24 November 2010
ª 2010 Published by Elsevier Ltd on behalf of European Society for
Vascular Surgery.
doi:10.1016/j.ejvs.2010.10.011
Percutaneous Access for Endovascular Aortic
Aneurysm Repair. Potential Predictors of Success must
be ReappraisedDear Editor,
Thank you for the excellent systematic review on
percutaneous access for endovascular aneurysm repair
(pe-EVAR).1 Data abstraction reveals that, relevant studies
published online several months before Malkawi et al.
submission, were ommitted.1 Evidence of significantly
lower primary success rates with increasing sheath size was
mentioned.1 This fact remains a logical scenario but con-
flicting results appeared after the largest available study by
Eisenack et al. (adding another 500 patients or 904 femoral
groins) with negligible effect of sheath size on success
rate.2 Instead, the significant issue of operator experience,
had the pivotal role in predicting pe-EVAR outcomes.2
Considering all 4 missing studies, and a recent study by
Krajcer et al.,3 adding totally 714 more patients (1219
femoral groins), thus w40% expansion of the previous
review population, and when splitting all pe-EVAR litera-
ture in two equal quantitative periods, (1st: 1999e2008 and
2nd: 2008e2010, initial 1450 and latest 1509 femoral accessTable 1 Early and late pe-EVAR results.
Patients Femoral
access sites
Mean sheath
size used (Fr)
Ove
succ
1st period
(1999e2008)
917 1450 17.7 88.7
2nd period
(2008e2010)
884 1509 18.8 95.4
Total 1801 2959 92.4
DR-OC: device-related open conversions, PR-OC: patient-related open
a Reported on pre-close technique femoral access entry site basis.
DOI of original article: 10.1016/j.ejvs.2010.02.001.sites respectively) we found that (Table 1) the earlier
period had worse primary success rate (88.7% vs 95.4%) and
increased combined device-related and patient-related
open conversion rates (8.6% vs 3.4%).
Considering that mean sheath size is almost the same,
and assuming that learning curves are rather similar among
institutions, this discrepancy might be explained by oper-
ator expertise. Interestingly, increasing experience elimi-
nates other potential predictors of pe-EVAR success rates
like sheath size or anatomically related factors, like
obesity.2
A meta-analysis is warranted to further clarify the contri-
bution of all possible predictor of success in pe-EVAR era.
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ess ratea
DR-/PR-OC’sa(%) P value
104 (7.1)/22 (1.5)
50 (3.3)/2 (0.13)
(weighted mean) 154 (5.2%)/24 (0.8%) <0.001/<0.001
conversions.
